Kamada Ltd. - Ordinary Shares (KMDA)

As a hedge fund portfolio manager reviewing KMDA, the double-digit organic growth trajectory stands out. With H1 2026 revenues hitting a record $100.2 million and adjusted EBITDA margins holding firm at 26%, the operational execution is stellar. Reaffirming the full-year 2026 guidance of $200 million to $205 million gives strong visibility, making the recent cash dividend declaration of $0.17 per share a clear signal of management's capital allocation confidence and cash generation strength.

From our risk management desk, we are closely tracking the disclosures in Kamada's Form 20-F. While the financial top- and bottom-line growth—like the 40% year-over-year net income jump in 2025—is impressive, the business model maintains a high degree of product and U.S. market concentration. Core therapies like KEDRAB, GLASSIA, and CMV immune globulin anchor a massive share of total revenues, meaning any unexpected regulatory or partnership shift involving Takeda on GLASSIA royalties could introduce unforeseen headwinds.

In evaluating our specialty pharma allocation, KMDA’s proprietary product segment—supplying roughly 87% of total revenues—demonstrates durable fundamental health. Underlying demand continues to scale upward despite a minor Q1 shipment timing noise that was swiftly resolved in April. The balance sheet remains liquid, backed by $29.4 million in cash and cash equivalents and $40.6 million in short-term investments as of mid-2026, providing a solid cushion for potential business development and MandA activities.

Observing the market reaction on the TASE and NASDAQ, the adoption of an annual cash dividend policy represents a structural maturation for KMDA. Distributing approximately $9.8 million in September 2026 highlights that the firm is transitioning from a purely growth-focused specialty biotech into a profitable, dividend-paying commercial player capable of self-funding its organic expansion and pursuing strategic acquisitions.

On our quant desk, running regression models on KMDA’s historical performance highlights the reliability of their seasonal cash generation. Operating cash flows reached $25.5 million in 2025, and the H1 2026 numbers confirm that profitability is scaling proportionally with revenue. With Adjusted EBITDA expected to land between $50 million and $53 million for the full year 2026, current valuation multiples look increasingly attractive relative to peers delivering similar organic growth.